Treatment of Hyponatremia in Patients with Acute Neurological Injury
BACKGROUND: Little data exist regarding the practice of sodium management in acute neurologically injured patients. This study describes the practice variations, thresholds for treatment, and effectiveness of treatment in this population.
METHODS: This retrospective, multicenter, observational study identified 400 ICU patients, from 17 centers, admitted for ≥48 h with subarachnoid hemorrhage (SAH), traumatic brain injury (TBI), intraparenchymal hemorrhage, or intracranial tumors between January 1, 2011 and July 31, 2012. Data collection included demographics, APACHE II, Glascow Coma Score (GCS), serum sodium (Na+), fluid rate and tonicity, use of sodium-altering therapies, intensive care unit (ICU) and hospital length of stay, and modified Rankin score upon discharge. Data were collected for the first 21 days of ICU admission or ICU discharge, whichever came first. Sodium trigger for treatment defined as the Na+ value prior to treatment with response defined as an increase of ≥4 mEq/L at 24 h.
RESULTS: Sodium-altering therapy was initiated in 34 % (137/400) of patients with 23 % (32/137) having Na+ >135 mEq/L at time of treatment initiation. The most common indications for treatment were declining serum Na+ (68/116, 59 %) and cerebral edema with mental status changes (21/116, 18 %). Median Na+ treatment trigger was 133 mEq/L (IQR 129-139) with no difference between diagnoses. Incidence and treatment of hyponatremia was more common in SAH and TBI [SAH (49/106, 46 %), TBI (39/97, 40 %), ICH (27/102, 26 %), tumor (22/95, 23 %); p = 0.001]. The most common initial treatment was hypertonic saline (85/137, 62 %), followed by oral sodium chloride tablets (42/137, 31 %) and fluid restriction (15/137, 11 %). Among treated patients, 60 % had a response at 24 h. Treated patients had lower admission GCS (12 vs. 14, p = 0.02) and higher APACHE II scores (12 vs. 10, p = 0.001). There was no statistically significant difference in outcome when comparing treated and untreated patients.
CONCLUSION: Sodium-altering therapy is commonly employed among neurologically injured patients. Hypertonic saline infusions were used first line in more than half of treated patients with the majority having a positive response at 24 h. Further studies are needed to evaluate the impact of various treatments on patient outcomes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Neurocritical care - 27(2017), 2 vom: 24. Okt., Seite 242-248 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Human, Theresa [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 22.08.2018 Date Revised 10.12.2019 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1007/s12028-016-0343-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM267697759 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM267697759 | ||
| 003 | DE-627 | ||
| 005 | 20231224221242.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12028-016-0343-x |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0892.xml |
| 035 | |a (DE-627)NLM267697759 | ||
| 035 | |a (NLM)28054290 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Human, Theresa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Treatment of Hyponatremia in Patients with Acute Neurological Injury |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.08.2018 | ||
| 500 | |a Date Revised 10.12.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Little data exist regarding the practice of sodium management in acute neurologically injured patients. This study describes the practice variations, thresholds for treatment, and effectiveness of treatment in this population | ||
| 520 | |a METHODS: This retrospective, multicenter, observational study identified 400 ICU patients, from 17 centers, admitted for ≥48 h with subarachnoid hemorrhage (SAH), traumatic brain injury (TBI), intraparenchymal hemorrhage, or intracranial tumors between January 1, 2011 and July 31, 2012. Data collection included demographics, APACHE II, Glascow Coma Score (GCS), serum sodium (Na+), fluid rate and tonicity, use of sodium-altering therapies, intensive care unit (ICU) and hospital length of stay, and modified Rankin score upon discharge. Data were collected for the first 21 days of ICU admission or ICU discharge, whichever came first. Sodium trigger for treatment defined as the Na+ value prior to treatment with response defined as an increase of ≥4 mEq/L at 24 h | ||
| 520 | |a RESULTS: Sodium-altering therapy was initiated in 34 % (137/400) of patients with 23 % (32/137) having Na+ >135 mEq/L at time of treatment initiation. The most common indications for treatment were declining serum Na+ (68/116, 59 %) and cerebral edema with mental status changes (21/116, 18 %). Median Na+ treatment trigger was 133 mEq/L (IQR 129-139) with no difference between diagnoses. Incidence and treatment of hyponatremia was more common in SAH and TBI [SAH (49/106, 46 %), TBI (39/97, 40 %), ICH (27/102, 26 %), tumor (22/95, 23 %); p = 0.001]. The most common initial treatment was hypertonic saline (85/137, 62 %), followed by oral sodium chloride tablets (42/137, 31 %) and fluid restriction (15/137, 11 %). Among treated patients, 60 % had a response at 24 h. Treated patients had lower admission GCS (12 vs. 14, p = 0.02) and higher APACHE II scores (12 vs. 10, p = 0.001). There was no statistically significant difference in outcome when comparing treated and untreated patients | ||
| 520 | |a CONCLUSION: Sodium-altering therapy is commonly employed among neurologically injured patients. Hypertonic saline infusions were used first line in more than half of treated patients with the majority having a positive response at 24 h. Further studies are needed to evaluate the impact of various treatments on patient outcomes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Hyponatremia | |
| 650 | 4 | |a Intensive care unit | |
| 650 | 4 | |a Intracerebral hemorrhage | |
| 650 | 4 | |a Intracranial tumor | |
| 650 | 4 | |a Neurocritical care | |
| 650 | 4 | |a Subarachnoid hemorrhage | |
| 650 | 4 | |a Traumatic brain injury | |
| 650 | 7 | |a Saline Solution, Hypertonic |2 NLM | |
| 650 | 7 | |a Sodium Chloride |2 NLM | |
| 650 | 7 | |a 451W47IQ8X |2 NLM | |
| 700 | 1 | |a Cook, Aaron M |e verfasserin |4 aut | |
| 700 | 1 | |a Anger, Brian |e verfasserin |4 aut | |
| 700 | 1 | |a Bledsoe, Kathleen |e verfasserin |4 aut | |
| 700 | 1 | |a Castle, Amber |e verfasserin |4 aut | |
| 700 | 1 | |a Deen, David |e verfasserin |4 aut | |
| 700 | 1 | |a Gibbs, Haley |e verfasserin |4 aut | |
| 700 | 1 | |a Lesch, Christine |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Norah |e verfasserin |4 aut | |
| 700 | 1 | |a McAllen, Karen |e verfasserin |4 aut | |
| 700 | 1 | |a Morrison, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Parker, Dennis |c Jr |e verfasserin |4 aut | |
| 700 | 1 | |a Rowe, A Shaun |e verfasserin |4 aut | |
| 700 | 1 | |a Rhoney, Denise |e verfasserin |4 aut | |
| 700 | 1 | |a Sangha, Kiranpal |e verfasserin |4 aut | |
| 700 | 1 | |a Santayana, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Taylor, Scott |e verfasserin |4 aut | |
| 700 | 1 | |a Tesoro, Eljim |e verfasserin |4 aut | |
| 700 | 1 | |a Brophy, Gretchen |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neurocritical care |d 2004 |g 27(2017), 2 vom: 24. Okt., Seite 242-248 |w (DE-627)NLM157737888 |x 1556-0961 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2017 |g number:2 |g day:24 |g month:10 |g pages:242-248 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12028-016-0343-x |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2017 |e 2 |b 24 |c 10 |h 242-248 | ||